- €1.53bn
- €1.42bn
- €221.39m
Annual balance sheet for Pharma Mar SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 202 | 182 | 163 | 155 | 167 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 78.9 | 59 | 47.8 | 42 | 60.6 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 295 | 275 | 253 | 250 | 283 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 30.6 | 34.7 | 47.6 | 59.1 | 60.1 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 368 | 393 | 341 | 350 | 395 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 86.3 | 97.3 | 95.9 | 82.7 | 93.9 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 190 | 170 | 147 | 141 | 143 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | 178 | 223 | 193 | 208 | 252 |
| Total Liabilities & Shareholders' Equity | 368 | 393 | 341 | 350 | 395 |
| Total Common Shares Outstanding |